Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of anle138b in Healthy Volunteers
NCT04208152Phase 1Completed
- Sponsor
- MODAG
- Start
- Dec 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of emrusolmin in Parkinson's disease (PD) and multiple system atrophy (MSA), sponsored by MODAG. Primary endpoints: Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses, Incidence of treatment-emergent changes in clinical laboratory parameters (SAD) and 7 more. Started Dec 2019; status: completed.
02
Drugs
emrusolmin
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT04208152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208152.